Description
Ascendis Pharma Jumps 7.5% on Rumors—Is a European Mega Deal in the Works?
Ascendis Pharma shares surged 7.5% this week following renewed takeover chatter sparked by a Betaville “uncooked” alert. According to traders citing the alert, a Switzerland-based pharmaceutical giant and another European firm are eyeing the Danish biotech, reigniting speculation first reported last month. The rumor has reignited investor interest in Ascendis, whose stock had already been on a recovery path after a strong Q3 2025 performance that included positive operating income and global momentum in its lead products, YORVIPATH and SKYTROFA. While no names have been confirmed, and the companies involved remain silent, the possibility of a strategic acquisition has amplified trading activity and speculation around Ascendis’ valuation and future direction.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
